PARP inhibitorPhase 3 trialInvestigational
Capivasertib
How it works
Blocks the activity of the PARP protein, which is involved in the repair of DNA damage in cancer cells.
Cancer types
Lung Cancer— All patients
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Capivasertib and Abiraterone for Prostate Cancer with PTEN Deficiency | Prostate Cancer | phase-3 | — | Source → |
| Capivasertib and Fulvestrant for Advanced or Metastatic Breast Cancer in Chinese Patients | Breast Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.